<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04508608</url>
  </required_header>
  <id_info>
    <org_study_id>SciCoRIC</org_study_id>
    <secondary_id>АААА-А15-115123110026-3</secondary_id>
    <nct_id>NCT04508608</nct_id>
  </id_info>
  <brief_title>Scintigraphic Evaluation of Contractile and Coronary Reserve in Patients With Ischemic Cardiomyopathy</brief_title>
  <acronym>SciCoRIC</acronym>
  <official_title>Scintigraphic Evaluation of Contractile and Coronary Reserve in Patients With Ischemic Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tomsk National Research Medical Center of the Russian Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tomsk National Research Medical Center of the Russian Academy of Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to single-photon emission computed tomography, the left ventricular contractile and&#xD;
      coronary flow reserve (CFR) will be assessed in patients with ischemic cardiomyopathy.&#xD;
      According to these data, the criteria for predicting the effectiveness of complex surgical&#xD;
      treatment of this pathology will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before surgical intervention, all patients pass routine clinical analyzes undergo coronary&#xD;
      angiography and 2D echocardiography. Some of patients in the ICM-1 and ICM-2 groups undergo&#xD;
      stress echocardiography with dobutamine.&#xD;
&#xD;
      Coronary arteriography is performed using the Axiom Artis (Siemens; Erlangen, Germany) and&#xD;
      transthoracic two-dimensional Doppler echocardiography (TTE) with the Acuson Sequoia 512&#xD;
      (Siemens; Erlangen, Germany)).&#xD;
&#xD;
      Besides, all of the ICM-1 and ICM-2 groups patients undergo myocardial perfusion imaging.&#xD;
      Standard two-day stress-rest imaging protocol is used. Adenosine at a dosage of 140&#xD;
      mcg/kg/min (for 4 min) is used as a pharmaceutical stress agent.&#xD;
&#xD;
      ICM-1 group and Control group for GBPS undergo gated blood pool SPECT (GBPS) at rest and&#xD;
      during increasing doses of dobutamine (5/10/15 μg/kg/min) (n = 60) ICM-2 group and Control&#xD;
      group for CFR undergo dynamic SPECT (n = 40). This investigation is combined with routine&#xD;
      myocardial perfusion imaging so patients are not exposed to extra stress.&#xD;
&#xD;
      Than ICM patients undergo surgical treatment of ICM in different volume. All of them receive&#xD;
      coronary bypass grafting (CABG); some patients undergo the left ventricular reconstruction&#xD;
      and intervention on the mitral valve.&#xD;
&#xD;
      In the early postoperative period (7-14 days), the ICM-1 group undergo rest GBPS and ICM-2&#xD;
      group undergo dynamic SPECT by two-day protocol. All patients undergo TTE too.&#xD;
&#xD;
      After at least 12 month, all patients undergo TTE to assess the presence of left ventricular&#xD;
      (LV) remodeling.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Actual">September 1, 2021</completion_date>
  <primary_completion_date type="Actual">September 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with an ongoing LV remodeling and reverse LV remodeling.</measure>
    <time_frame>12 month</time_frame>
    <description>Ongoing LV remodeling is meant increase of LV end-systolic volume (LVESV) or decrease of LVESV≤10% according to 2D echocardiography in comparison to early postoperative period study. Reverse LV remodeling is meant decrease in LVESV &gt;10% according to 2D echocardiography in comparison to early postoperative period study.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>Ischemic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Ischemic cardiomyopathy group - 1 (ICM-1)</arm_group_label>
    <description>Inclusion criteria:&#xD;
History of myocardial infarction (MI) or revascularization (CABG or PCI);&#xD;
&gt; 75% stenosis of left main or proximal left anterior descending artery (LAD) and/ or stenosis of &gt; 75% of ≥2 epicardial vessels (based on coronary angiography (CA) data);&#xD;
LV ejection fraction (EF) &lt;40% and increase in LV volumes according to echocardiography (ECHO)&#xD;
Exclusion criteria:&#xD;
Presence of contraindications to the stress test with inotropic stimulation;&#xD;
inflammatory myocardial diseases;&#xD;
the presence of severe hematological, neurological disorders, other psychosomatic conditions that impede research;&#xD;
life expectancy of less than 6 months (acute renal and hepatic failure, mental illness, malignant neoplasms of the final stages, unsuitable correction of brain injury).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ischemic cardiomyopathy group - 2 (ICM-2)</arm_group_label>
    <description>Inclusion criteria:&#xD;
History of myocardial infarction (MI) or revascularization (CABG or PCI);&#xD;
&gt; 75% stenosis of left main or proximal LAD and/ or stenosis of &gt; 75% of ≥2 epicardial vessels (based on coronary angiography (CA) data);&#xD;
LV EF &lt;40% and increase in LV volumes according to echocardiography (ECHO)&#xD;
Exclusion criteria:&#xD;
Presence of contraindications to the stress test with inotropic stimulation;&#xD;
inflammatory myocardial diseases;&#xD;
the presence of severe hematological, neurological disorders, other psychosomatic conditions that impede research;&#xD;
life expectancy of less than 6 months (acute renal and hepatic failure, mental illness, malignant neoplasms of the final stages, unsuitable correction of brain injury).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group for GBPS.</arm_group_label>
    <description>Inclusion criteria:&#xD;
Absence of obstructive coronary artery lesion;&#xD;
Absence of history of MI and revascularization.&#xD;
Exclusion criteria:&#xD;
Presence of contraindications to the stress test with inotropic stimulation;&#xD;
inflammatory myocardial diseases;&#xD;
the presence of severe hematological, neurological disorders, other psychosomatic conditions that impede research;&#xD;
life expectancy of less than 6 months (acute renal and hepatic failure, mental illness, malignant neoplasms of the final stages, unsuitable correction of brain injury).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group for CFR.</arm_group_label>
    <description>Presence of obstructive coronary artery lesion;&#xD;
Indications for coronary artery bypass grafting&#xD;
Exclusion criteria:&#xD;
Presence of contraindications to the adenosine stress test;&#xD;
inflammatory myocardial diseases;&#xD;
the presence of severe hematological, neurological disorders, other psychosomatic conditions that impede research;&#xD;
life expectancy of less than 6 months (acute renal and hepatic failure, mental illness, malignant neoplasms of the final stages, unsuitable correction of brain injury).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Stress Gated blood pool SPECT</intervention_name>
    <description>After labeling of red blood cells in vivo, a sequential series of acquisition is carried out at rest and during increasing doses of dobutamine (5/10/15 μg / kg / min). The duration of acquisition is 300 seconds.&#xD;
The acquisitions are carried out on dedicated cardiac gamma-camera with ultrafast Cadmium zinc telluride (CZT) detectors (DiscoveryNM530c, General electric Healthcare Israel, Israel)</description>
    <arm_group_label>Control group for GBPS.</arm_group_label>
    <arm_group_label>Ischemic cardiomyopathy group - 1 (ICM-1)</arm_group_label>
    <other_name>Stress radionuclide angiography</other_name>
    <other_name>Stress radionuclide ventriculography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Dynamic SPECT</intervention_name>
    <description>The passage of a radiopharmaceutical bolus through the cavities of the heart and myocardium at rest and during infusion of adenosine at a dosage of 140 mcg / kg / min (for 4 minutes) is recorded.&#xD;
At the peak of the stress test (after 2 minutes of administration of adenosine), a 5 ml bolus (dose 260-444 MBq) of 99mTc-methoxyisobutylisonitrile (MIBI) is administered at a rate of 1 ml / s. Immediately after the end of tracer administration, 30 ml of 0.9% sodium chloride (NaCl) is infused. A scintigraphic recording of the study begins 5 seconds before the administration of the radiopharmaceutical.&#xD;
The next day, the study at rest is carried out. Scintigraphic images are recorded in tomographic mode with ECG synchronization for 600 s, at list mode.&#xD;
The acquisitions are carried out on dedicated cardiac gamma-camera with ultrafast CZT detectors (DiscoveryNM530c, General electric Healthcare Israel, Israel)</description>
    <arm_group_label>Control group for CFR.</arm_group_label>
    <arm_group_label>Ischemic cardiomyopathy group - 2 (ICM-2)</arm_group_label>
    <other_name>Radionuclide coronary flow reserve assessement</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients being living in Russian Federation (inc.ethnic minorities)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        А) For ICM group:&#xD;
&#xD;
          1. History of myocardial infarction (MI) or revascularization (CABG or PCI);&#xD;
&#xD;
          2. &gt; 75% stenosis of left main or proximal LAD and/ or stenosis of &gt; 75% of ≥2 epicardial&#xD;
             vessels (based on coronary angiography (CA) data);&#xD;
&#xD;
          3. LV EF &lt;40% and increase in LV volumes according to echocardiography (ECHO)&#xD;
&#xD;
        B) For GBPS Control group&#xD;
&#xD;
          1. Absence of obstructive coronary artery lesion;&#xD;
&#xD;
          2. Absence of history of MI and revascularization.&#xD;
&#xD;
        C) For CFR Control group&#xD;
&#xD;
          1. Presence of obstructive coronary artery lesion;&#xD;
&#xD;
          2. Indications for coronary artery bypass grafting;&#xD;
&#xD;
        Exclusion Criteria (for all groups):&#xD;
&#xD;
          1. Presence of contraindications to the stress test with inotropic stimulation;&#xD;
&#xD;
          2. Inflammatory myocardial diseases;&#xD;
&#xD;
          3. The presence of severe hematological, neurological disorders, other psychosomatic&#xD;
             conditions that impede research;&#xD;
&#xD;
          4. Life expectancy of less than 6 months (acute renal and hepatic failure, mental&#xD;
             illness, malignant neoplasms of the final stages, unsuitable correction of brain&#xD;
             injury).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konstantin Zavadovsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiology Research Institute, Tomsk National Research Medical Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences</name>
      <address>
        <city>Tomsk</city>
        <zip>634000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 7, 2020</study_first_submitted>
  <study_first_submitted_qc>August 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2020</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ischemic Cardiomyopathy</keyword>
  <keyword>Single photon emission computed tomography</keyword>
  <keyword>Gated blood pool SPECT</keyword>
  <keyword>Coronary flow reserve</keyword>
  <keyword>Prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

